Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly EBIT of -$116.2 million for Q1 2026, down 23.76% year-over-year from -$152.4 million in Q1 2025, and up 5.36% quarter-over-quarter from -$122.7 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBIT history runs 14 years deep, the most recent figure standing at -$116.2 million for Q1 2026.
- In Q1 2026, EBIT fell 23.76% year-over-year to -$116.2 million; the TTM figure through Mar 2026 stood at -$385.7 million (down 14.45% YoY), while the FY2025 annual figure was -$363.4 million, down 21.52% from the prior year.
- EBIT for Q1 2026 stood at -$116.2 million, up from -$122.7 million in the prior quarter.
- The five-year high for EBIT was -$25.9 million in Q1 2022, with the low at -$122.7 million in Q4 2025.
- The 5-year median for EBIT is -$71.5 million (2023), against an average of -$68.7 million.
- The sharpest annual moves came in 2023 and 2025: EBIT plunged 179.94% in 2023, then surged 52.07% in 2025.
- Viridian Therapeutics, Inc.\DE's EBIT stood at -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then slipped by 22.38% to -$87.5 million in 2024, then slumped by 40.33% to -$122.7 million in 2025, then climbed by 5.36% to -$116.2 million in 2026.
- Business Quant data shows VRDN's EBIT at -$116.2 million in Q1 2026, -$122.7 million in Q4 2025, and -$40.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -126.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -126.27 Mn |
| Mar 31, 2026 | -116.17 Mn |
| Dec 31, 2025 | -122.75 Mn |
| Sep 30, 2025 | -40.01 Mn |
| Jun 30, 2025 | -106.77 Mn |
| Mar 31, 2025 | -93.87 Mn |
| Dec 31, 2024 | -87.47 Mn |
| Sep 30, 2024 | -83.48 Mn |
| Jun 30, 2024 | -72.19 Mn |
| Mar 31, 2024 | -55.90 Mn |
| Dec 31, 2023 | -71.48 Mn |
| Sep 30, 2023 | -51.22 Mn |
| Jun 30, 2023 | -59.28 Mn |
| Mar 31, 2023 | -72.47 Mn |
| Dec 31, 2022 | -49.07 Mn |
| Sep 30, 2022 | -29.79 Mn |
| Jun 30, 2022 | -29.56 Mn |
| Mar 31, 2022 | -25.89 Mn |
| Dec 31, 2021 | -29.08 Mn |
| Sep 30, 2021 | -14.13 Mn |